Format

Send to:

Choose Destination
See comment in PubMed Commons below
Endocrine. 2004 Mar-Apr;23(2-3):135-41.

Therapy of ED: PDE-5 Inhibitors.

Author information

  • 1The Department of Urology, College of Physicians and Surgeons of Columbia Universiy, New York, NY, USA. rshabsigh@urology.cpmc.columbia.edu

Abstract

The development of phosphodiesterase inhibitors, which are selective for the type 5 isoenzyme, has revolutionized the initial evaluation and treatment of men with erectile dysfunction. These agents can be taken orally and are effective in 60-70% of patients with erectile dysfunction, and they have low incidences of side effects when taken as recommended. The major contraindications are concomitant use with nitrates or the alpha-blockers terazosin and doxazosin. The major difference in the three approved inhibitors is that tadalafil has a considerably longer serum half-life, which provides a longer window of opportunity and potentially side effects.

Copyright 2004 Humana Press Inc.

PMID:
15146092
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk